MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-369-7100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.91 million
Profitability
Miscellaneous
Employees32
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma Inc (NASDAQ:MEIP) issued its earnings results on Wednesday, August, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.18. The firm had revenue of $1.13 million for the quarter, compared to analysts' expectations of $1.05 million. MEI Pharma had a negative return on equity of 76.61% and a negative net margin of 819.04%. View MEI Pharma's Earnings History.
When is MEI Pharma's next earnings date?
What price target have analysts set for MEIP?
3 Wall Street analysts have issued twelve-month price objectives for MEI Pharma's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate MEI Pharma's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 461.8% from the stock's current price. View Analyst Price Targets for MEI Pharma.
What is the consensus analysts' recommendation for MEI Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.
What are Wall Street analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (9/3/2019)
- 2. HC Wainwright analysts commented, "$10 PT ICML data update points to expanded opportunity in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). On the heels of reporting promising data in follicular lymphoma (FL) at ASCO earlier this month, MEI Pharma presented more color on its ongoing Phase 1b study in B-cell lymphomas in an oral presentation at ICML. Herein, we highlight the newly reported 100% objective response rates (ORR) with favorable safety in CLL/ SLL, which we believe may bring PI3K inhibition back in the game in the highly competitive CLL/SLL landscape (discussed below)." (6/24/2019)
Has MEI Pharma been receiving favorable news coverage?
News coverage about MEIP stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MEI Pharma earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for MEI Pharma.
Are investors shorting MEI Pharma?
MEI Pharma saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 529,400 shares, a drop of 12.1% from the August 30th total of 602,000 shares. Based on an average daily volume of 304,800 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.9% of the shares of the company are sold short. View MEI Pharma's Current Options Chain.
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include Basilea Pharmaceutica (BPMUF), INDIVIOR PLC/S (INVVY), Myovant Sciences (MYOV), Retrophin (RTRX), Viking Therapeutics (VKTX), Lannett (LCI), Urogen Pharma (URGN), Milestone Pharmaceuticals (MIST), ChemoCentryx (CCXI), Aptorum Group (APM), BioDelivery Sciences International (BDSI), Sinovac Biotech (SVA), Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH) and Progenics Pharmaceuticals (PGNX).
What other stocks do shareholders of MEI Pharma own?
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)
- Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)
- Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)
- Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)
- Mr. David A. Walsey, VP of IR & Corp. Communications
Who are MEI Pharma's major shareholders?
MEI Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bailard Inc. (0.24%). Company insiders that own MEI Pharma stock include Charles V Baltic III, Christine Anna White and David M Urso. View Institutional Ownership Trends for MEI Pharma.
Which institutional investors are selling MEI Pharma stock?
How do I buy shares of MEI Pharma?
Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEIP stock can currently be purchased for approximately $1.78.
How big of a company is MEI Pharma?
MEI Pharma has a market capitalization of $126.90 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.
What is MEI Pharma's official website?
How can I contact MEI Pharma?
MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]
MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
